Evidence map›Paper›PMID 25713928›Full record

ArticleACS chemical neuroscience2015

A Cyclic Peptide Mimic of the β-Amyloid Binding Domain on Transthyretin.

Patricia Y Cho, Gururaj Joshi, Melissa D Boersma, Jeffrey A Johnson, Regina M Murphy

Abstract read
In one paragraph

Article in ACS chemical neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. ROSETTA-informed design of structurally stabilized cyclic anti-amyloid peptides.Protein engineering, design & selection : PEDS · 2019
    Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Patricia Y Cho†Department of Chemical and Biological Engineering, ‡School of Pharmacy, and §Biotechnology Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States.
Gururaj Joshi†Department of Chemical and Biological Engineering, ‡School of Pharmacy, and §Biotechnology Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States.
Melissa D Boersma†Department of Chemical and Biological Engineering, ‡School of Pharmacy, and §Biotechnology Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States.
Jeffrey A Johnson†Department of Chemical and Biological Engineering, ‡School of Pharmacy, and §Biotechnology Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States.
Regina M Murphy†Department of Chemical and Biological Engineering, ‡School of Pharmacy, and §Biotechnology Center, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States.
University of Wisconsin–Madison · US

Funding

Tranthyretin's Regulatory Role in Beta-Amyloid Aggregation and ToxicityR01AG033493 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI JOHNSON, JEFFREY A, MURPHY, REGINA M. · 2009 to 2016
$2.7M
NIA NIH HHS R01 AG033493NIA NIH HHS R01AG033493
6 · The paper itself

Abstract

Self-association of β-amyloid (Aβ) into oligomers and fibrils is associated with Alzheimer's disease (AD), motivating the search for compounds that bind to and inhibit Aβ oligomerization and/or neurotoxicity. Peptides are an attractive class of such compounds, with potential advantages over small molecules in affinity and specificity. Self-complementation and peptide library screening are two strategies that have been employed in the search for peptides that bind to Aβ. Alternatively, one could design Aβ-binding peptides based on knowledge of complementary binding proteins. One candidate protein, transthyretin (TTR), binds Aβ, inhibits aggregation, and reduces its toxicity. Previously, strand G of TTR was identified as part of a specific Aβ binding domain, and G16, a 16-mer peptide with a sequence that spans strands G and H of TTR, was synthesized and tested. Although both TTR and G16 bound to Aβ, they differed significantly in their effect on Aβ aggregation, and G16 was less effective than TTR at protecting neurons from Aβ toxicity. G16 lacks the β-strand/loop/β-strand structure of TTR's Aβ binding domain. To enforce proper residue alignment, we transplanted the G16 sequence onto a β-hairpin template. Two peptides with 18 and 22 amino acids were synthesized using an orthogonally protected glutamic acid derivative, and an N-to-C cyclization reaction was carried out to further restrict conformational flexibility. The cyclized 22-mer (but not the noncyclized 22-mer nor the 18-mer) strongly suppressed Aβ aggregation into fibrils, and protected neurons against Aβ toxicity. The imposition of structural constraints generated a much-improved peptidomimetic of the Aβ binding epitope on TTR.

Indexed as

Amyloid beta-PeptidesAnimalsHumansMicePeptides, CyclicPrealbuminProtein BindingProtein Structure, QuaternaryAmyloid beta-PeptidesPeptides, CyclicPrealbuminAlzheimer’s diseaseamyloid fibrilsBeta-amyloidcyclic peptidepeptidomimeticstransthyretin

Identifiers

PMID25713928
PMCPMC4797071
OpenAlexW2328264188

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.